Exploding Topics puts 2025 GLP-1 drug revenue at $79 billion
The thread also estimates that about 11% of US adults were on a GLP-1 drug for weight loss as of mid-2026.
Recap by typeshit. Post by Exploding Topics on X.
See it on X
More peptides
-
Korea approves Mounjaro for cardiovascular risk reduction and kids with type 2 diabetes 
Korea approves Mounjaro for cardiovascular risk reduction and kids with type 2 diabetes
The MFDS approval rests on SURPASS-CVOT, where Mounjaro matched Trulicity on heart events in 13,000+ patients but did not prove superior.
-
Galderma, Natura and L'Oréal develop products aimed at Ozempic face 
Galderma, Natura and L'Oréal develop products aimed at Ozempic face
Inside Retail Asia looks at skincare and aesthetic treatments brands are building for facial volume loss after rapid weight loss.
-
Ram Kapoor says take Ozempic without worry, but workouts still matter Ram Kapoor says take Ozempic without worry, but workouts still matter
The actor told an interviewer people can take Ozempic carefree, while stressing that nothing replaces actually working out.
-
Dr Reddy's plans to relaunch semaglutide in Canada in November after supply fix Dr Reddy's plans to relaunch semaglutide in Canada in November after supply fix
CFO MV Narasimham says the company still expects to ship 6 to 7 million pens across 10 approved markets between November and March, with Canada taking most of them.
-
Oral Wegovy is reportedly set to launch in Israel next week 
Oral Wegovy is reportedly set to launch in Israel next week
Investseekers cites Israeli TV reports that Novo Nordisk is preparing to bring the Wegovy pill to Israel within days.
-
MedPage Today roundup flags weak eating disorder safeguards in the GLP-1 boom 
MedPage Today
peptides typeshitSafetyMedPage Today roundup flags weak eating disorder safeguards in the GLP-1 boom
A mental health news roundup points to a New York Times report that patients with eating disorders have little protection as GLP-1 use grows.
